Article
Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.
BMC cancer - 11 Jun 2010
Thangasamy Thilakavathy, Sittadjody Sivanandane, Mitchell Geoffrey C, Mendoza Erin E, Radhakrishnan Vijayababu M, Limesand Kirsten H, Burd Randy
Abstract excerpt
BACKGROUND: The alkylating agent dacarbazine (DTIC) has been used in the treatment of melanoma for decades, but when used as a monotherapy for cancer only moderate response rates are achieved. Recently, the clinical use of temozolomide (TMZ) has become the more commonly used analog of DTIC-related oral agents because of its greater bioavailability and ability to cross the blood brain barrier. The response rates...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
